Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (Mabthera) [rituximab] during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapse B-cell non-Hodgkin lymphoma (HOVON 44 study)

Next Previous
Trial Profile

A randomised phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (Mabthera) [rituximab] during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapse B-cell non-Hodgkin lymphoma (HOVON 44 study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cytarabine; Dexamethasone; Dexamethasone; Etoposide; Filgrastim; Ifosfamide; Melphalan; Methotrexate
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 44 NHL; HOVON 44 STUDY

    • Most Recent Events

    • 08 Aug 2013 Planned number of patients changed from 300 to 340 as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Additional lead trial centres and investigators identified as reported by Netherlands Trial Register record.
    • 20 Oct 2009 Planned number of patients changed from 296 to 300 as reported by Netherlands Trial Register record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top